Latest filing published 06 Mar 2018 for Aimmune Therapeutics, Inc..
No signal scores available.
Filings by Jeffrey H. Knapp span 2 companies, the busiest being Affymax Inc and Aimmune Therapeutics, Inc. In total, 70 filings cover trades dated from 16 April 2012 to 4 March 2018.
On the market, this insider has only sold: 23 sales, €2.2M in total. Outside the open market, there are 4 share grants and 43 option exercises.
The latest filing, published on 6 March 2018, reports a share grant in Aimmune Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 70 declarations